BR112022008565A2 - Composto, composição farmacêutica, conjugado, métodos para tratar câncer e um distúrbio relativo à proteína ras - Google Patents
Composto, composição farmacêutica, conjugado, métodos para tratar câncer e um distúrbio relativo à proteína rasInfo
- Publication number
- BR112022008565A2 BR112022008565A2 BR112022008565A BR112022008565A BR112022008565A2 BR 112022008565 A2 BR112022008565 A2 BR 112022008565A2 BR 112022008565 A BR112022008565 A BR 112022008565A BR 112022008565 A BR112022008565 A BR 112022008565A BR 112022008565 A2 BR112022008565 A2 BR 112022008565A2
- Authority
- BR
- Brazil
- Prior art keywords
- conjugate
- compound
- methods
- pharmaceutical composition
- treat cancer
- Prior art date
Links
- 206010028980 Neoplasm Diseases 0.000 title abstract 3
- 239000008194 pharmaceutical composition Substances 0.000 title abstract 3
- 201000011510 cancer Diseases 0.000 title abstract 2
- 150000001875 compounds Chemical class 0.000 title abstract 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 title abstract 2
- 102000016914 ras Proteins Human genes 0.000 abstract 2
- 108010014186 ras Proteins Proteins 0.000 abstract 2
- 102000007474 Multiprotein Complexes Human genes 0.000 abstract 1
- 108010085220 Multiprotein Complexes Proteins 0.000 abstract 1
- 230000002401 inhibitory effect Effects 0.000 abstract 1
- 150000002678 macrocyclic compounds Chemical class 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D245/00—Heterocyclic compounds containing rings of more than seven members having two nitrogen atoms as the only ring hetero atoms
- C07D245/04—Heterocyclic compounds containing rings of more than seven members having two nitrogen atoms as the only ring hetero atoms condensed with carbocyclic rings or ring systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D498/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains three hetero rings
- C07D498/18—Bridged systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/50—Pyridazines; Hydrogenated pyridazines
- A61K31/504—Pyridazines; Hydrogenated pyridazines forming part of bridged ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5386—1,4-Oxazines, e.g. morpholine spiro-condensed or forming part of bridged ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D498/22—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains four or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
- C07D513/22—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains four or more hetero rings
Landscapes
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Veterinary Medicine (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Plural Heterocyclic Compounds (AREA)
Abstract
COMPOSTO, COMPOSIÇÃO FARMACÊUTICA, CONJUGADO, MÉTODOS PARA TRATAR CÂNCER E UM DISTÚRBIO RELATIVO À PROTEÍNA RAS. A divulgação apresenta compostos macrocíclicos e composições farmacêuticas e complexos de proteínas dos mesmos, capazes de inibir proteínas Ras e seus usos no tratamento de cânceres.
Applications Claiming Priority (11)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201962930355P | 2019-11-04 | 2019-11-04 | |
| US62/930,355 | 2019-11-04 | ||
| US201962951652P | 2019-12-20 | 2019-12-20 | |
| US62/951,652 | 2019-12-20 | ||
| US202063000357P | 2020-03-26 | 2020-03-26 | |
| US63/000,357 | 2020-03-26 | ||
| US202063011636P | 2020-04-17 | 2020-04-17 | |
| US63/011,636 | 2020-04-17 | ||
| US202063043588P | 2020-06-24 | 2020-06-24 | |
| US63/043,588 | 2020-06-24 | ||
| PCT/US2020/058841 WO2021091982A1 (en) | 2019-11-04 | 2020-11-04 | Ras inhibitors |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| BR112022008565A2 true BR112022008565A2 (pt) | 2022-08-09 |
| BR112022008565B1 BR112022008565B1 (pt) | 2024-07-02 |
Family
ID=
Also Published As
| Publication number | Publication date |
|---|---|
| TW202132316A (zh) | 2021-09-01 |
| US20230234929A1 (en) | 2023-07-27 |
| CN114786777A (zh) | 2022-07-22 |
| CN115894606A (zh) | 2023-04-04 |
| IL292644A (en) | 2022-07-01 |
| MX2022005359A (es) | 2022-06-02 |
| US11952352B2 (en) | 2024-04-09 |
| KR20220109408A (ko) | 2022-08-04 |
| CO2022006033A2 (es) | 2022-07-29 |
| WO2021091982A1 (en) | 2021-05-14 |
| AU2020379734A1 (en) | 2022-05-05 |
| US11566007B2 (en) | 2023-01-31 |
| CA3159561A1 (en) | 2021-05-14 |
| PE20221278A1 (es) | 2022-09-05 |
| EP4054719A1 (en) | 2022-09-14 |
| JP2022553858A (ja) | 2022-12-26 |
| CL2023000974A1 (es) | 2023-09-29 |
| CR20220241A (es) | 2022-08-03 |
| US20210130303A1 (en) | 2021-05-06 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| BR112022008535A2 (pt) | Composto, composição farmacêutica, métodos para tratar câncer e um distúrbio relativo à proteína ras | |
| BR112022008534A2 (pt) | Compostos, composição farmacêutica, conjugado e métodos para tratar câncer e para tratar um distúrbio relacionado à proteína ras | |
| BR112023022819A2 (pt) | Compostos, composição farmacêutica, conjugados e métodos para tratar câncer em um sujeito, para tratar um distúrbio e para inibir uma proteína ras em uma célula | |
| MX2022005359A (es) | Inhibidores de ras. | |
| MX2023003060A (es) | Derivados indolicos como inhibidores de ras en el tratamiento del cancer. | |
| SA521422304B1 (ar) | مركبات تشارك في الارتباط التعاوني واستخداماتها | |
| PH12019502545A1 (en) | Anti-cdh6 antibody and anti-cdh6 antibody-drug conjugate | |
| MX2023013084A (es) | Inhibidores de ras para el tratamiento del cancer. | |
| MX2021001807A (es) | Combinacion de un inhibidor de histona desacetilasa y un inhibidor de proteina cinasa y uso farmaceutico de la misma. | |
| MX2024004247A (es) | Inhibidores de la ras. | |
| BR112018006817A2 (pt) | método de tratamento do câncer | |
| CR20240276A (es) | Inhibidores de la ras | |
| BR112019018615A2 (pt) | compostos antimicrobianos, composições e usos dos mesmos | |
| EA201690321A1 (ru) | Применение иммуноконъюгата антитела к muc1 и майтанзиноида для лечения солидных опухолей | |
| BR112021026170A2 (pt) | Composição farmacêutica para tratamento de tumor?? | |
| BR112022000251A2 (pt) | Derivados macrocíclicos de espirociclo como inibidores de mcl-1 | |
| EA202090741A1 (ru) | Конъюгаты антитела к тканевому фактору и лекарственного средства и их применение в лечении рака | |
| BR112021025732A2 (pt) | Inibidores macrocíclicos de mcl-1 | |
| BR112022011372A2 (pt) | Inibidores de interação de proteína a de replicação (rpa)-dna | |
| TW202444726A (zh) | Ｒａｓ抑制劑 | |
| BR112022025610A2 (pt) | Composto ou sal farmaceuticamente aceitável do mesmo, método de preparo do composto, composição para inibir agregação e hiperfosforilação de proteína tau, e composição farmacêutica | |
| BR112022007632A2 (pt) | Composição farmacêutica e preparação de kit para tratamento de câncer, e, métodos para tratamento de câncer e de um paciente com câncer | |
| BR112016004511A8 (pt) | Composto, composto ou uma forma do mesmo, uso de um composto ou forma do mesmo, e composição farmacêutica para uso no tratamento de um câncer mediado por bmi-1 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| B154 | Notification of filing of divisional application [chapter 15.50 patent gazette] |
Free format text: O PEDIDO FOI DIVIDIDO NO BR122023011393-4 PROTOCOLO 870230049402 EM 09/06/2023 15:05. |
|
| B09A | Decision: intention to grant [chapter 9.1 patent gazette] | ||
| B16A | Patent or certificate of addition of invention granted [chapter 16.1 patent gazette] |
Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 04/11/2020, OBSERVADAS AS CONDICOES LEGAIS |